{"id":8373,"date":"2021-12-14T23:34:14","date_gmt":"2021-12-14T23:34:14","guid":{"rendered":"https:\/\/epitomestaging.com\/tnc\/?page_id=8373"},"modified":"2026-03-31T17:04:11","modified_gmt":"2026-03-31T17:04:11","slug":"active-clinical-research-studies","status":"publish","type":"page","link":"https:\/\/epitomestaging.com\/tnc\/active-clinical-research-studies\/","title":{"rendered":"Active Clinical Research Studies"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Home 2 Content Pg&#8221; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#bbe4ed&#8221; background_image=&#8221;https:\/\/epitomestaging.com\/tnc\/wp-content\/uploads\/2022\/02\/rsz-tnc-header-engagement-1000&#215;200-1.jpg&#8221; background_size=&#8221;initial&#8221; background_position=&#8221;top_center&#8221; width_phone=&#8221;auto&#8221; width_last_edited=&#8221;off|desktop&#8221; max_width_last_edited=&#8221;off|desktop&#8221; module_alignment=&#8221;center&#8221; min_height_tablet=&#8221;300px&#8221; min_height_last_edited=&#8221;off|desktop&#8221; height=&#8221;200px&#8221; height_tablet=&#8221;154px&#8221; height_phone=&#8221;100px&#8221; height_last_edited=&#8221;on|phone&#8221; max_height_tablet=&#8221;300px&#8221; max_height_phone=&#8221;300px&#8221; max_height_last_edited=&#8221;off|desktop&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; top_divider_height_tablet=&#8221;&#8221; top_divider_height_phone=&#8221;50px&#8221; top_divider_height_last_edited=&#8221;on|phone&#8221; bottom_divider_style=&#8221;curve&#8221; bottom_divider_color=&#8221;#FFFFFF&#8221; bottom_divider_height=&#8221;70px&#8221; bottom_divider_arrangement=&#8221;above_content&#8221; bottom_divider_height_tablet=&#8221;70px&#8221; bottom_divider_height_phone=&#8221;50px&#8221; bottom_divider_height_last_edited=&#8221;on|desktop&#8221; background_last_edited=&#8221;on|tablet&#8221; background_image_phone=&#8221;https:\/\/epitomestaging.com\/tnc\/wp-content\/uploads\/2022\/02\/rsz-tnc-mobile-stars.jpg&#8221; background_enable_image_phone=&#8221;on&#8221; parallax_tablet=&#8221;off&#8221; parallax_phone=&#8221;off&#8221; background_size_tablet=&#8221;contain&#8221; background_size_phone=&#8221;initial&#8221; background_position_tablet=&#8221;top_center&#8221; background_position_phone=&#8221;top_right&#8221; background_enable_video_mp4_tablet=&#8221;off&#8221; background_enable_video_mp4_phone=&#8221;off&#8221; module_alignment_tablet=&#8221;right&#8221; module_alignment_phone=&#8221;left&#8221; module_alignment_last_edited=&#8221;off|desktop&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;1_2,1_2&#8243; use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;0px||||false|false&#8221; custom_padding=&#8221;0px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text content_tablet=&#8221;<\/p>\n<h1>Patient Engagement<\/h1>\n<p>&#8221; content_phone=&#8221;<\/p>\n<h1>Patient Engagement<\/h1>\n<p>&#8221; content_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; z_index=&#8221;10&#8243; custom_margin=&#8221;30px||||false|false&#8221; custom_margin_tablet=&#8221;30px||||false|false&#8221; custom_margin_phone=&#8221;|0%|||false|false&#8221; custom_margin_last_edited=&#8221;on|phone&#8221; custom_padding=&#8221;|187px|||false|false&#8221; custom_padding_tablet=&#8221;|427px|||false|false&#8221; custom_padding_phone=&#8221;|0px|||false|false&#8221; custom_padding_last_edited=&#8221;on|desktop&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1>For Patients<\/h1>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_margin=&#8221;20px||21px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;0px|0px|0|0px|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Clinical Research Studies<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.20.0&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_margin=&#8221;20px||30px||false|false&#8221; custom_padding=&#8221;40px|0px|0px|0|false|false&#8221; hover_enabled=&#8221;0&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;][et_pb_row column_structure=&#8221;1_3,1_3,1_3&#8243; use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;1&#8243; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;0px|0px|0px|0px|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p class=\"research-button\"><a href=\"#cdkl5\">CDKL5 Deficiency Disorder &gt; <\/a><a href=\"#cags\">Chopra-Amiel-Gordon Syndrome &gt;<\/a> <a href=\"#ds\">Down Syndrome &gt; \u00a0 <\/a><a href=\"#dravets\">Dravet Syndrome &gt;<\/a><a href=\"#dmd\">Duchenne Muscular Dystrophy &gt;<\/a><a href=\"#epi\">Epilepsy &gt;<\/a> \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0<a href=\"#fa\">Friedreich&#8217;s Ataxia &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"research-button\"><a href=\"#grin\">GRIN-Related Neurodevelopmental Disorder &gt;<\/a><a href=\"#mecp2\">MECP2 Duplication Syndrome &gt;<\/a>\u00a0<a href=\"#gmg\">Myasthenia Gravis &gt;<\/a> <a href=\"#mydy\">Myotonic Dystrophy &gt;<\/a><a href=\"#nemy\">Nemaline Myopathy &gt;<\/a><a href=\"#pms\">Phelan-McDermid Syndrome &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p class=\"research-button\"><a href=\"#phts\">PTEN Hamartoma Syndrome &gt;<\/a> <a href=\"#rett\">Rett Syndrome &gt;<\/a><a href=\"#sma\">Spinal Muscular Atrophy &gt;<\/a><a href=\"#sws\">Sturge Weber Syndrome &gt;<\/a> <a href=\"#tsc\">Tuberous Sclerosis Complex &gt;<\/a><a href=\"#xlmymy\">X-Linked Myotubular Myopathy &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;asd&#8221; _builder_version=&#8221;4.20.2&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;0px|0px|0|0px|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; header_2_text_color=&#8221;#000000&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Active TNC Clinical Research Studies<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;cags&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Accelerating Clinical Trial Readiness Innovations for Monogenic Neurodevelopmental Disorders (ACTION) Initiative<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/translationalneurosciencecenter.org\/action-initiative\/\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#000000&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;cdkl5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>CDKL5 Deficiency Disorder<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/www.childrenshospital.org\/conditions\/cdkl5-disorder\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.20.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#000000&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>International CDKL5 Clinical Research Network\u2019s Clinical Trial Readiness Study<\/h3>\n<p>PI: Heather Olson, MD, MS- <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05558371?cond=NCT05558371&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT05558371<\/a><\/p>\n<p>Patient Advocacy Group Partner: <a href=\"https:\/\/www.cdkl5.com\/\" target=\"_blank\" rel=\"noopener\">International Foundation for CDKL5 Research (IFCR)<\/a><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Endpoint Enabling Study of Cyclin-dependent kinase-like 5 (CDKL5) Deficiency Disorder (CANDID)<\/h3>\n<p>PI: Heather Olson, MD, MS &#8211; <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05373719?cond=NCT05373719&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT05373719<\/a><\/p>\n<p>Patient Advocacy Group Partner: <a href=\"https:\/\/www.louloufoundation.org\/\" target=\"_blank\" rel=\"noopener\">LouLou Foundation <\/a><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 Deficiency Disorder Followed by an Open-Label Extension<\/h3>\n<p>PI: Christelle Achkar, MD &#8211; <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05064878?cond=NCT05064878&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT05064878<\/a><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3><span>Phase 1 Study of Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies<\/span><\/h3>\n<p>PI: Heather Olson, MD, MS &#8211; <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06700811?cond=NCT06700811&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT06700811<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;cags&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Chopra-Amiel-Gordon Syndrome (CAGS)<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/www.childrenshospital.org\/conditions-treatments\/chopra-amiel-gordon-syndrome\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#000000&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome<\/h3>\n<p>PI: Maya Chopra, MBBS, FRACP \u2013 <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05528744?term=ankrd17&amp;amp;draw=2&amp;amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT05528744<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;ds&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Down Syndrome<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/www.childrenshospital.org\/conditions\/down-syndrome\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#000000&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Treatment Efficacy and Safety of ADHD Medication in Down Syndrome \u2013 TEAM-DS<br \/>Down Syndrome<\/h3>\n<p>PI: Sabrina Sargado, MD \u2014\u00a0<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04219280?cond=NCT04219280&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT04219280<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;dravets&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; hover_enabled=&#8221;0&#8243; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Dravet Syndrome<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#000000&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3><span>EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome<\/span><\/h3>\n<p>PI: Christelle <span>Achkar<\/span>, MD \u2014 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06872125?cond=NCT06872125&amp;viewType=Card&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT06872125<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;dmd&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Duchenne Muscular Dystrophy (DMD)<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/www.childrenshospital.org\/conditions-treatments\/duchenne-muscular-dystrophy\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#000000&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3><span>A Long-Term Multicenter Prospective Observational Study Evaluating the Comparative Effectiveness and Safety of Sarepta Gene Transfer Therapy vs. Standard of Care in Participants with Duchnne Muscular Dystrophy under Conditions of Routine Clinical Practice<\/span><\/h3>\n<p>PI: <span>Partha Ghosh, MD<\/span>\u00a0\u2014 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06270719?cond=NCT06270719&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT06270719<\/a><span>\u200b<\/span><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3><span>A Prospective, Observational Study Evaluating the Real-World Experience of Givinostat in Patients with Duchenne Muscular Dystrophy<\/span><\/h3>\n<p>PI: <span>Partha Ghosh, MD<\/span>\u00a0\u2014 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07127978?cond=NCT07127978&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT07127978<\/a><\/p>\n<p>Patient Advocacy Group Partner: <span><a href=\"https:\/\/www.mda.org\/\" target=\"_blank\" rel=\"noopener\">Muscular Dystrophy Association<\/a>, <a href=\"https:\/\/www.ParentProjectMD.org\/\" target=\"_blank\" rel=\"noopener\">Parent Project Muscular Dystrophy (PPMD)<\/a>\u200b<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;epi&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Epilepsy<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/www.childrenshospital.org\/conditions\/epilepsy\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.20.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px|0px|40px|0px|false|false&#8221; border_width_bottom=&#8221;1px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3 class=\"trial-head\"><span style=\"color: #000000;\">Epilepsy Seizure Detection with Innovative Tripolar EEG (tEEG)<\/span><\/h3>\n<p>PI: Alexander Rotenberg MD, PhD \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05944692?cond=NCT05944692&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT05944692<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;fa&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Friedreich&#8217;s Ataxia (FA)<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.20.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px|0px|40px|0px|false|false&#8221; border_width_bottom=&#8221;1px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3 class=\"trial-head\"><span style=\"color: #000000;\"><span>Characteristics and Clinical Course of Disease In Participants with Cardiomyopathy Associated With Friedreich Ataxia<\/span><\/span><\/h3>\n<p>PI: Leslie Hayes, MD \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06865482?cond=NCT06865482&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT06865482<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;grin&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>GRIN-related Neurodevelopmental Disorder<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.20.0&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;2px||40px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#000000&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.20.0&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; border_style_bottom=&#8221;none&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Open-Label Extension to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder<\/h3>\n<p>PI: Christelle Achkar, MD &#8211; <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07224581?term=A%20Phase%201b%2F3%20Study%20in%20GRIN-related%20Neurodevelopmental%20Disorder&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT07224581<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;mecp2&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>MECP2 Duplication Syndrome<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.20.0&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;2px||40px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#000000&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.20.0&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; border_style_bottom=&#8221;none&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>A Phase 1-2, Double-Blind, Sham-Controlled Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Patients With MECP2 Duplication Syndrome<\/h3>\n<p>PI: David Lieberman, MD, PhD &#8211; <span role=\"presentation\"><\/span> <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06430385?term=ION440&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT06430385<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;gmg&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Myasthenia Gravis<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/www.childrenshospital.org\/conditions\/myasthenia-gravis\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.20.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px|0px|40px|0px|false|false&#8221; border_width_bottom=&#8221;1px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)<\/h3>\n<p>PI: Partha Ghosh, MD \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05644561?cond=NCT05644561&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT05644561<\/a><\/p>\n<p>Patient Advocacy Group Parnter: <a href=\"https:\/\/myasthenia.org\/\" target=\"_blank\" rel=\"noopener\">Myasthenia Gravis Foundation of America (MGFA)<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;mydy&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 class=\"trial-head\">Myotonic Dystrophy<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.20.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px|0px|40px|0px|false|false&#8221; border_width_bottom=&#8221;1px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>A Phase 1\/2, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects with Myotonic Dystrophy Type 1 (DM1) (Galileo)<\/h3>\n<p>PI: Leslie Hayes, MD\u2014 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06185764?cond=NCT06185764&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT06185764<\/a><\/p>\n<p>Patient Advocacy Group Partner: <a href=\"https:\/\/www.mda.org\/\" target=\"_blank\" rel=\"noopener\">Muscular Dystrophy Association (MDA)\u00a0<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;nemy&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 class=\"trial-head\">Nemaline Myopathy<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.20.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px|0px|40px|0px|false|false&#8221; border_width_bottom=&#8221;1px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Nemaline Myopathy natural history study &#8211; Assessing Individuals with Nemaline Myopathy (NM-CTRN)<\/h3>\n<p>PI: Leslie Hayes, MD\u2014 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06774703?cond=NCT06774703&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT06774703<\/a><\/p>\n<p>Patient Advocacy Group Partners: <a href=\"https:\/\/www.mda.org\/\" target=\"_blank\" rel=\"noopener\">Muscular Dystrophy Association (MDA)\u00a0<\/a>, <a href=\"https:\/\/www.curecmd.org\/\" target=\"_blank\" rel=\"noopener\">Cure CMD<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;pms&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 class=\"trial-head\">Phelan-McDermid Syndrome (PMS)<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; min_height=&#8221;0.8px&#8221; custom_css_main_element=&#8221;float: right;&#8221; border_color_bottom=&#8221;#000000&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/www.childrenshospital.org\/conditions\/phelan-mcdermid-syndrome\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.20.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px|0px|40px|0px|false|false&#8221; border_width_bottom=&#8221;1px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3><span>A Phase 1\/2, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, and Clinical Activity Study of a Single Dose of JAG201 Gene Therapy Delivered Via Intracerebroventricular Administration in Participants With SHANK3 Haploinsufficiency<\/span><\/h3>\n<p>PI: <span>Siddharth Srivastava, MD<\/span> \u2014 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06662188\" target=\"_blank\" rel=\"noopener\">NCT06662188<\/a><\/p>\n<p>Patient Advocacy Group Partners: <a href=\"https:\/\/pmsf.org\/\" target=\"_blank\" rel=\"noopener\">Phelan McDermid Syndrome Foundation, <\/a><a href=\"https:\/\/www.cureshank.org\/?gad_source=1&amp;gad_campaignid=21109027380&amp;gclid=EAIaIQobChMI3LzZjeu1kQMVwE5HAR2DzytvEAAYASAAEgLcZfD_BwE\" data-outlook-id=\"f04f074c-8b9a-4db7-9946-adfcf02fdeb4\" title=\"https:\/\/www.cureshank.org\/?gad_source=1&amp;gad_campaignid=21109027380&amp;gclid=EAIaIQobChMI3LzZjeu1kQMVwE5HAR2DzytvEAAYASAAEgLcZfD_BwE\">CureSHANK<\/a><\/p>\n<h3>Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome<\/h3>\n<p>PI: Mustafa Sahin, MD, PhD \u2014 <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02461420\" target=\"_blank\" rel=\"noopener\"> NCT02461420 <\/a><\/p>\n<p>Patient Advocacy Group Partners: <a href=\"https:\/\/pmsf.org\/\" target=\"_blank\" rel=\"noopener\">Phelan McDermid Syndrome Foundation<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;phts&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_margin=&#8221;0px||||false|false&#8221; custom_padding=&#8221;30px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 class=\"trial-head\">PTEN Hamartoma Syndrome (PHTS)<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_css_main_element=&#8221;float: right;&#8221; border_color_bottom=&#8221;#000000&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/www.childrenshospital.org\/conditions\/pten-hamartoma-tumor-syndrome\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.20.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px|0px|40px|0px|false|false&#8221; border_width_bottom=&#8221;1px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations<\/h3>\n<p>PI: Mustafa Sahin, MD, PhD\u00a0 |\u00a0 Natural History Study \u2014 <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02461446\" target=\"_blank\" rel=\"noopener\"> NCT02461446 <\/a><\/p>\n<p>Patient Advocacy Group Partners: <a href=\"https:\/\/ptenfoundation.org\/\" target=\"_blank\" rel=\"noopener\">PTEN Foundation<\/a>, <a href=\"https:\/\/www.ptenresearch.org\/\" target=\"_blank\" rel=\"noopener\">PTEN Research<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;rett&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 class=\"trial-head\">Rett Syndrome<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_css_main_element=&#8221;float: right;&#8221; border_color_bottom=&#8221;#000000&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/www.childrenshospital.org\/conditions-treatments\/rett-syndrome\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#000000&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>An Open-label Phase 1\/2\/3 Study Consisting of a Phase 1\/2 Safety and Dose-escalation and Phase 3 Dose-expansion Study to Evaluate Safety and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy in Females With Rett Syndrome<\/h3>\n<p>PI: David Lieberman, MD, PhD &#8211; <span role=\"presentation\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05606614?term=Taysha%20REVEAL&amp;rank=2\" data-outlook-id=\"8a01d9b8-53fc-45f9-88b4-a4c54911ad24\" title=\"https:\/\/clinicaltrials.gov\/study\/NCT05606614?term=Taysha%20REVEAL&amp;rank=2\">NCT05606614<\/a><\/span><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Neurogene- A Phase 1\/2, Open-Label Clinical Study to Evaluate Safety, Tolerability, and Efficacy of NGN-401 in Pediatric Subjects with Rett Syndrome<\/h3>\n<p>PI: David Lieberman, MD, PhD\u00a0 |\u00a0 Interventional Therapeutic Trial \u2014 <a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05898620\" target=\"_blank\" rel=\"noopener\"><span>NCT05898620<\/span><\/a><\/p>\n<p>Patient Advocacy Group Partner: <a href=\"https:\/\/www.neurogene.com\/\" target=\"_blank\" rel=\"noopener\">NEUROGENE INC<\/a><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>IRSF Rett Syndrome Observational Registry<\/h3>\n<p>PI: David Lieberman, MD, PhD\u2014 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05432349?cond=NCT05432349&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT05432349<\/a><\/p>\n<p>Patient Advocacy Group Partner: <a href=\"https:\/\/www.rettsyndrome.org\/\" target=\"_blank\" rel=\"noopener\">International Rett Syndrome Foundation<\/a><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Validating Innovative Biosensors for Rett Autonomic Symptom Tracking (VIBRANT)<\/h3>\n<p>PI: David Lieberman, MD, PhD\u2014<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06338267?cond=NCT06338267&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT06338267<\/a><\/p>\n<p>Patient Advocacy Group Partner: <a href=\"https:\/\/reverserett.org\/\" target=\"_blank\" rel=\"noopener\">Rett Syndrome Research Trust (RSRT)<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;sma&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_margin=&#8221;||0px|||&#8221; custom_padding=&#8221;30px|0px|0px|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 class=\"trial-head\">Spinal Muscular Atrophy (SMA)<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_css_main_element=&#8221;float: right;&#8221; border_color_bottom=&#8221;#000000&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/www.childrenshospital.org\/conditions-treatments\/spinal-muscular-atrophy-sma\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_color_bottom=&#8221;#000000&#8243; border_style_bottom=&#8221;none&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;1px|||||&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>A 2 part, seamless, multi-center, randomized, placebo-controlled, double blind study to investigate the safety, tolerability, pharmokinetics, pharmodynamics, and efficacy of RO7204239 in combination with Risdiplam (RO7034067) in ambulant patients with spinal muscular atrophy. (MANATEE)<\/h3>\n<p>PI: Basil Darras, MD \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05115110?cond=NCT05115110&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT05115110<\/a><\/p>\n<p>Patient Advocacy Group Partners: <a href=\"https:\/\/www.curesma.org\/\" target=\"_blank\" rel=\"noopener\">Cure SMA<\/a>, <a href=\"https:\/\/www.mda.org\/\" target=\"_blank\" rel=\"noopener\">Muscular Dystrophy Association<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#000000&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;1px|||||&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>An Open Label, Single Cohort Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered via the ThecaFlex DRx\u2122 System (PIERRE-PK)<\/h3>\n<p>PI: Basil Darras, MD \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06555419?cond=NCT06555419&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT06555419<\/a><\/p>\n<p>Patient Advocacy Group Partners: <a href=\"https:\/\/www.curesma.org\/\" target=\"_blank\" rel=\"noopener\">Cure SMA<\/a>, <a href=\"https:\/\/www.mda.org\/\" target=\"_blank\" rel=\"noopener\">Muscular Dystrophy Association<\/a><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;1px|||||&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>AVXS long term f\/u&#8211;A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101 (SPECTRUM)<\/h3>\n<p>PI: Leslie Hayes, MD \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05335876?cond=NCT05335876&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT05335876<\/a><\/p>\n<p>Patient Advocacy Group Partners: <a href=\"https:\/\/www.curesma.org\/\" target=\"_blank\" rel=\"noopener\">Cure SMA<\/a>, <a href=\"https:\/\/www.mda.org\/\" target=\"_blank\" rel=\"noopener\">Muscular Dystrophy Association<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;sws&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 class=\"trial-head\">Sturge-Weber Syndrome<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/www.childrenshospital.org\/conditions\/sturge-weber-syndrome\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_color_bottom=&#8221;#000000&#8243; border_style_bottom=&#8221;none&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Integrated Longitudinal Studies to Identify Biomarkers and Therapeutic Strategies for Sturge-Weber Syndrome<\/h3>\n<p>PI: <span>John McLaren, MD<\/span> \u00a0|\u00a0 Natural History Study \u2014 <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04717427\" target=\"_blank\" rel=\"noopener\"> NCT04717427 <\/a><\/p>\n<p>Patient Advocacy Group Partner: <a href=\"https:\/\/sturge-weber.org\/\" target=\"_blank\" rel=\"noopener\">Sturge-Weber Foundation<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#000000&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;1px|||||&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>MRI Biomarkers in Patients with Sturge Weber Syndrome<\/h3>\n<p>PI: <span>John McLaren, MD<\/span> \u2013<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04517565?cond=NCT04517565&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT04517565<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;tsc&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 class=\"trial-head\">Tuberous Sclerosis Complex (TSC)<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_css_main_element=&#8221;float: right;&#8221; border_color_bottom=&#8221;#000000&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/www.childrenshospital.org\/conditions\/tuberous-sclerosis-complex-tsc\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.20.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_color_bottom=&#8221;#000000&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study (TSC-STEPS)<\/h3>\n<p>PI: Mustafa Sahin MD, PhD\u00a0 |\u00a0 Clinical Drug Trial \u2014 <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05104983\" target=\"_blank\" rel=\"noopener\"> NCT05104983 <\/a><\/p>\n<p>Patient Advocacy Group Partner: <a href=\"https:\/\/www.tscalliance.org\/\" target=\"_blank\" rel=\"noopener\">TSC Alliance<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_style_all=&#8221;none&#8221; border_color_bottom=&#8221;#000000&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)<\/h3>\n<p>PI: Mustafa Sahin MD, PhD\u00a0 |\u00a0 Natural History Study \u2014 <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02461459\" target=\"_blank\" rel=\"noopener\"> NCT02461459 <\/a><\/p>\n<p>Patient Advocacy Group Partner: <a href=\"https:\/\/www.tscalliance.org\/\" target=\"_blank\" rel=\"noopener\">TSC Alliance<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;xlmymy&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_padding=&#8221;30px|0px|0|0|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_css_main_element=&#8221;display: flex;&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 class=\"trial-head\">X-Linked Myotubular Myopathy<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_color=&#8221;off&#8221; custom_css_main_element=&#8221;float: right;&#8221; border_color_bottom=&#8221;#000000&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p class=\"learn-more\"><a href=\"https:\/\/www.childrenshospital.org\/conditions\/x-linked-myotubular-myopathy\" target=\"_blank\" rel=\"noopener\">Learn More &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.20.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;0px||40px||false|false&#8221; border_width_bottom=&#8221;1px&#8221; border_color_bottom=&#8221;#000000&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition (EXCEL)<\/h3>\n<p>PI: Leslie Hayes, MD \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06581146?cond=NCT06581146&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT06581146<\/a><\/p>\n<p>Patient Advocacy Group Partner: <a href=\"https:\/\/www.curecmd.org\/\" target=\"_blank\" rel=\"noopener\">Cure CMD<\/a>, <a href=\"https:\/\/www.mda.org\/\" target=\"_blank\" rel=\"noopener\">Muscular Dystrophy Association (MDA)<\/a>, <a href=\"https:\/\/www.joshuafrase.org\/\" target=\"_blank\" rel=\"noopener\">Joshua Frase Foundation<\/a>\u00a0<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px|30px|false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3><span>A Phase 1\/2, Multicenter, Open-label, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2957 in Male Participants with Invasive Ventilator-dependent X-linked Myotubular Myopathy<\/span><\/h3>\n<p>PI: Leslie Hayes, MD \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07052929?cond=NCT07052929&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT07052929<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>For PatientsClinical Research StudiesCDKL5 Deficiency Disorder &gt; Chopra-Amiel-Gordon Syndrome &gt; Down Syndrome &gt; \u00a0 Dravet Syndrome &gt;Duchenne Muscular Dystrophy &gt;Epilepsy &gt; \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0Friedreich&#8217;s Ataxia &gt;GRIN-Related Neurodevelopmental Disorder &gt;MECP2 Duplication Syndrome &gt;\u00a0Myasthenia Gravis &gt; Myotonic Dystrophy &gt;Nemaline Myopathy &gt;Phelan-McDermid Syndrome &gt;PTEN Hamartoma Syndrome &gt; Rett Syndrome &gt;Spinal Muscular Atrophy &gt;Sturge Weber Syndrome [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-8373","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/epitomestaging.com\/tnc\/wp-json\/wp\/v2\/pages\/8373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/epitomestaging.com\/tnc\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/epitomestaging.com\/tnc\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/epitomestaging.com\/tnc\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/epitomestaging.com\/tnc\/wp-json\/wp\/v2\/comments?post=8373"}],"version-history":[{"count":220,"href":"https:\/\/epitomestaging.com\/tnc\/wp-json\/wp\/v2\/pages\/8373\/revisions"}],"predecessor-version":[{"id":13437,"href":"https:\/\/epitomestaging.com\/tnc\/wp-json\/wp\/v2\/pages\/8373\/revisions\/13437"}],"wp:attachment":[{"href":"https:\/\/epitomestaging.com\/tnc\/wp-json\/wp\/v2\/media?parent=8373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}